Last reviewed · How we verify
ABO1009-DP
At a glance
| Generic name | ABO1009-DP |
|---|---|
| Sponsor | Suzhou Abogen Biosciences Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant (COVID-19 Omicron) mRNA Vaccine (Phase 1) (PHASE1)
- A Study to Evaluate Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant (COVID-19) mRNA Vaccines (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ABO1009-DP CI brief — competitive landscape report
- ABO1009-DP updates RSS · CI watch RSS
- Suzhou Abogen Biosciences Co., Ltd. portfolio CI